此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

使用类固醇注射预防特发性声门下狭窄中气管狭窄复发 (ASTRO)

2026年11月10日 更新者:Johns Hopkins University

特发性声门下狭窄辅助性类固醇疗效研究

This study will examine the ability of steroid injections into the site of stenosis following surgical dilation to delay the need for repeated surgical dilations.

研究概览

研究类型

介入性

注册 (估计的)

226

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Alexander Hillel, M.D.
  • 电话号码:4432876006
  • 邮箱:ahillel@jh.edu

学习地点

    • California
      • San Diego、California、美国、92121
        • 尚未招聘
        • University of California - San Diego
        • 接触:
        • 首席研究员:
          • Daniel Cates, MD
      • San Francisco、California、美国、94115
        • 招聘中
        • University of California - San Francisco
        • 首席研究员:
          • Clark Rosen, MD
        • 接触:
    • Colorado
      • Aurora、Colorado、美国、80045
        • 尚未招聘
        • University of Colorado
        • 接触:
        • 首席研究员:
          • Matthew Clary, MD
    • Florida
      • Tampa、Florida、美国、33612
        • 招聘中
        • University of South Florida
        • 接触:
        • 首席研究员:
          • Yael Bensoussan, MD
    • Iowa
      • Iowa City、Iowa、美国、52242
        • 招聘中
        • University of Iowa Hospitals and Clinics
        • 接触:
        • 首席研究员:
          • Matthew Hoffman, MD, PhD
    • Maryland
      • Baltimore、Maryland、美国、21231
        • 招聘中
        • Johns Hopkins Hospital
        • 首席研究员:
          • Alexander Hillel, MD
        • 接触:
          • Sarah E Collins, M.S.
          • 电话号码:434-962-3058
          • 邮箱:shirsh1@jh.edu
        • 接触:
        • 副研究员:
          • Kevin Motz, MD
    • New York
      • Rochester、New York、美国、14642
        • 招聘中
        • University of Rochester Medical Center
        • 接触:
        • 首席研究员:
          • G. Todd Schneider, MD, MS
    • Tennessee
      • Nashville、Tennessee、美国、37232
        • 招聘中
        • Vanderbilt University Medical Center
        • 首席研究员:
          • Alexander Gelbard, MD
        • 接触:
    • Utah
      • Salt Lake City、Utah、美国、84112
        • 招聘中
        • University of Utah
        • 接触:
        • 首席研究员:
          • Breanne Schiffer, MD, MPH
    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • 尚未招聘
        • University of Wisconsin - Madison
        • 接触:
        • 首席研究员:
          • David Francis, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Diagnosis of iSGS following the NoAAC criteria which involves ruling out known causes for airway stenosis. Participants may be newly diagnosed or carry an existing diagnosis of iSGS;
  2. Age Range: 18 years to 80 years old at the time of consent;
  3. Sex distribution: all eligible men and women will be included, and no one will be excluded;
  4. Have a life expectancy of ≥6 months; and,
  5. ECOG performance status of 0 or 1.

Exclusion Criteria:

  1. History of subglottic stenosis from identifiable cause (not idiopathic), including any of the below clinical criteria:

    1. Prolonged endotracheal intubation or tracheostomy (intervention greater than 7 days immediately prior to diagnosis of subglottic stenosis);
    2. External physical trauma (including but not limited to blunt, penetration, chemical, or thermal injury) that causes injury to the subglottis;
    3. Clinical diagnosis of granulomatosis with polyangiitis (GPA);
    4. Radiation exposure to the neck;
    5. Complications resulting from the Index Procedure, including needing an endotracheal tube or tracheostomy immediately following surgery or a perforation of the trachea;
  2. Current or previous treatment with SILSI;

  3. Use of systemic corticosteroids (oral, intravenous, or intramuscular glucocorticoids), regardless of indication, within 7 days before triamcinolone administration;

    1. Local administration of corticosteroids (ophthalmic, intranasal, inhaled) is not prohibited. However, the administration of intraarticular corticosteroids during the Study Drug Dosing phase is not recommended due to potential increased risk of infection.
    2. Intralesional administration, in a site other than the subglottis, of corticosteroids should be discussed with the site PI before enrollment.
    3. Use of inhaled steroids is permitted during the study if the participant was taking at the time of consent, and no new inhaled steroids can be started while enrolled in the study.
  4. Intraarticular corticosteroids during the Study Drug Dosing phase due to potential increased risk of infection;

  5. Use of anticoagulants other than aspirin (daily aspirin dose should not exceed 81mg);

  6. Pulmonary disease including interstitial lung disease or COPD/emphysema;

  7. Systemic infection requiring treatment with antibiotics, antifungal, or antiviral agents within 21 days of Enrollment;

  8. Poorly controlled diabetes as defined by a HbA1C value greater or equal to 8.0 in the last 180 days;

  9. Participants with active cancer or a history of cancer in the last 5 years prior to enrollment, except for squamous or basal cell carcinoma of the skin;

  10. Participation in any clinical trial involving an investigational drug or device, within four weeks, or 5 half-lives of the investigational agent (whichever time point is longer) prior to enrollment or during this trial participation;

  11. Active autoimmune disease requiring systemic treatment;

  12. History of solid organ transplant due to use of immunosuppression;

  13. Contraindication to any aspect of the index procedure;

  14. Inability to tolerate in-office SILSI procedure;

  15. Contraindication, hypersensitivity, or history of intolerance to oral or injectable steroids;

  16. Contraindication to SMOFlipid including any of the below:

    1. Severe lipid metabolism disorders characterized by hypertriglyceridemia (greater than 500 mg/dL);
    2. Hypersensitivity to eggs, soybean, peanut protein, or any active ingredient in SMOFlipid;
    3. History of intolerance to SMOFlipid;
  17. Participants with known, suspected, or plan for becoming pregnant in the next 6 months after the index procedure, or participants who are breastfeeding;

  18. NYHA class II-IV heart failure within the past 6 months prior to Enrollment;

  19. History of angioedema;

  20. Lack of capacity to consent;

  21. Alcohol or substance abuse or dependence in the past 6 months prior to Enrollment;

  22. Participants who for any reason may not complete the study as judged by the PI;

  23. Participants planning to move to another city or state for 6 months after the Index Procedure;

  24. Not able to undergo phlebotomy as reported by the participant or determined by the study coordinator or physician.

  25. The presence of a medical condition, lab test result, and/or use of a medication and/or any substance, individually or in aggregate, that in the judgement of the site investigator could impair study participation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:病灶内曲安奈德类固醇注射

Intralesional Triamcinolone injection 3x at one, two, and three months following surgical dilation

安慰剂比较:病灶内安慰剂注射

Intralesional Placebo injection 3x at one, two, and three months following surgical dilation

研究衡量的是什么?

主要结果指标

结果测量
大体时间
峰值呼气流速变化(升/分钟)
大体时间:6个月
6个月

次要结果测量

结果测量
措施说明
大体时间
Clinical COPD Questionnaire
大体时间:6 months

Score range 0-60, Lower score indicates better health

6 months
Voice Handicap Index-10
大体时间:6 Months

Score range 0 to 40, Lower score indicates better voice

6 Months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Alexander Hillel, MD、Johns Hopkins University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月20日

初级完成 (估计的)

2031年1月1日

研究完成 (估计的)

2032年1月1日

研究注册日期

首次提交

2025年11月11日

首先提交符合 QC 标准的

2025年11月11日

首次发布 (实际的)

2025年11月14日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • IRB00507375
  • 1UG3HL173394-01A1 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 共享支持信息类型

  • 研究方案
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅